

1 **Prevalence and Determinant of Adverse Drug Reactions Among**
2 **MDR-TB Patients Attending St. Peter's TB Specialized Hospital,**
3 **Addis Ababa, Ethiopia.**

4 Fikru Letose Shararo^{1*}, Degemu Sahlu Asebe², Hawine Teshome Teshome³, Sahle Asfaw Jabo⁴,

5 Affiliation

6 ^{1*}Gambella Peoples' Regional National State Health Bureau, Gambella, Ethiopia.

7 ²College of health Science, department of public health, Selale University, Fiche, Ethiopia.

8 ³College of health science, Addis Ababa University, Addis Ababa, Ethiopia.

9 ⁴College of health Science, Kotbe metropolitan University, Addis Ababa, Ethiopia.

10 E-mail address: FL:fikruletose6@gmail.com, DS:kergadegemu@gmail.com,

11 HT:hawinetes@gmail.com, SA: sahleasfaw1919@gmail.com,

12 Corresponding Author: Fikru Letose Shararo; PO Box: 109; Mobile Number; +251921416858;

13 Email address: [fikruletose6@gmail.com]

14 FL: MPH

15 DS: MPH

16 HT: MPH

17 SA: MPH

18 Research type: Research article

20 **Abstract**

21 **Background:** Tuberculosis is one of a major public health problem throughout the world. About
22 9.6 million people were estimated to have Tuberculosis in 2014. Out of this, 480 000 cases were
23 multidrug-resistant Tuberculosis. Thus, it has to be identified, focused and prioritized for
24 subsequent and targeted interventions. Therefore, the aim this study was to assess the prevalence
25 and factors affecting adverse drug reaction among multidrug-resistant Tuberculosis patients.

26 **Method:** Institution based retrospective cross sectional study design was included all patients
27 with Multi Drug Resistant who were registered and treated from 9 January 2020 to 30 March
28 2020. Data abstraction form was used to obtain patient information from their cards. Data were
29 collected by trained nurses who have been working at multidrug-resistant Tuberculosis treatment
30 service. Data were entered, cleaned and checked using Epi Data version 4.6 statistical software
31 and analyzed by SPSS version 23. Bivariate and multivariate logistic regression analyses were
32 used to examine the association between independent and dependent variables. The results were
33 presented as Odds Ratio with 95% CI.

34 **Result:** A total of 286 patients were included in the study. The prevalence of adverse drug
35 reaction in this study were 169 (59.1%). Factors such as Treatment outcome and comorbidity
36 were significantly associated with adverse drug reaction among multidrug-resistant Tuberculosis
37 patients.

38 **Conclusion and Recommendation:** There was high prevalence of adverse drug reaction among
39 multidrug-resistant Tuberculosis patients. Comorbidity and treatment outcome were the
40 independent determinants. Patients who are identified with adverse drug events need special
41 attention enhanced clinical management.

42 **Key word:** Adverse drug reaction, MDR-TB, Institution based cross sectional study.

43 **Introduction**

44 Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis*; a rod-shaped
45 bacillus called “acid-fast” due to its staining characteristics in laboratory. Occasionally the
46 disease can also be caused by *Mycobacterium Ovis* and *Mycobacterium africanum*(1).

47 TB is considered drug-resistant when the TB causative agent is not killed by one or more of the
48 available anti-TB drugs. Drug-resistant TB can be primary or secondary (acquired). Primary
49 resistance is drug resistance among new cases, while secondary resistance is drug resistance
50 among previously treated cases(1, 2).

51 Treatment for multidrug-resistant Tuberculosis (MDR-TB) is longer, and requires more
52 expensive and more toxic drugs. For most patients with MDR-TB, the current regimens
53 recommended by WHO lasts 20 months and treatment success rates are much lower(3). In
54 Ethiopia, MDR-TB patients are treated with standardized second line treatment regimen for at
55 least 18-24 months. Drug Resistance Survey (DRS) data from representative patient populations
56 are used to design a standardized treatment regimen(2).

57 Globally, an estimated 3.3% of new TB cases and 20% of previously treated cases have MDR-
58 TB in 2014. From these MDR-TB cases, an estimated 190,000 people died. Despite the number
59 of TB deaths is unacceptably high, with a timely diagnosis and correct treatment almost all
60 people with TB can be cured(3).

61 The prevalence and mortality of Tuberculosis of all forms is estimated to be 546 and 73 per
62 100,000 populations respectively. In the year 2006/7 Ethiopia registered 129,743 cases of TB.
63 According to latest estimates, Ethiopia stands 7th in the list of High Burden Countries for TB.

64 According to the MOH hospital statistics data, tuberculosis is the leading cause of morbidity, the
65 third cause of hospital admission (after deliveries and malaria), and the second cause of death in
66 Ethiopia, after malaria(1).

67 Patients with MDR-TB take more tablets and receive more injections for a longer period of time,
68 may experience more adverse effects and require increased support to continue treatment and/or
69 to monitor adverse effects. Detecting and controlling adverse effects in a timely manner
70 promotes adherence and prevents default to treatment(1, 4).

71 Unmanaged adverse reactions greatly affect the patients' adherence to treatment regimen, which
72 in turn leads to the development of drug resistance(4). This study is intended to determine the
73 current management practice of adverse drug reactions among MDR-TB patients on second-line
74 anti-tuberculosis drug regimen. In addition, health care practitioners' knowledge and patient's
75 understanding of their treatments will be assessed with this study.

76 **Material and Methods**

77 **Study design, setting, and period**

78 Institution based retrospective cross sectional study was conducted at St. Peter's TB Specialized
79 Hospital from 9 January 2020 to 30 March 2020.

80 It was inaugurated on February 04, 1963 as "St. Peter's TB Clinic" by Emperor Haile Selassie I.
81 St. Peter's has served as the only specialised TB referral hospital in Ethiopia for four decades.
82 Afterwards, by the government's decision TB treatment centres were opened in every region of
83 the country and that has alleviated the burden which had been laid on St. Peter's. St. Peter's is
84 the first hospital to offer medical services to patients with drug resistant TB. The hospital has a

85 total of 400 staffs during the study period and 286 patients with MDR-TB who were registered
86 and treated during 9 January 2020 to 30 March 2020.

87 **Study participants and sampling procedures**

88 All MDR-TB patients who were treated with anti-TB drugs at St. Peter's TB Specialized
89 Hospital were the source population. Whereas, all MDR-TB patients attended St. Peter's TB
90 Specialized Hospital and treated by second- line anti-TB drugs and aged 18 and above were
91 study population. All records of patients who have been on treatment from 9 January 2020 to 30
92 March 2020 at St. Peter's TB Specialized Hospital were reviewed (**Fig 1**) and 286 patients
93 profile cards that fulfill the inclusion criteria were incorporated in the study.

94 **Data collection instruments and methods**

95 A data abstraction form was developed so as to meet the objectives of this study. It was used to
96 obtain the required information from the patient's medical chart. The form consisted of questions
97 regarding socio-demographic characteristics, clinical characteristics, treatment regimens, adverse
98 drug reactions and ADR managements. The list of patients needed for the study was obtained
99 from the hospital's database. After getting the list of the patients, their charts were retrieved from
100 the record and documentation office. A data abstraction format was used to record the necessary
101 information from patients' chart. The data were collected by trained nurses who are staff of
102 MDR-TB ward.

103 **Variables of the Study**

104 The dependent variable was adverse drug reactions. Whereas, the independent variables include
105 Age, Sex, Marital status, educational status, Occupational status, Co-morbidity, MI, Site of TB,

106 Anti-TB drugs, Treatment outcome, History of smoking, History of alcohol use and Drug abuse
107 history.

108 **Measurements**

109 **New:** A patient who has received no or less than one month of anti-tuberculosis treatment.

110 **Relapse:** A patient who was previously treated for TB and whose most recent treatment outcome
111 was “cured” or “treatment completed”, and who is subsequently diagnosed with recurrent
112 episode of TB.

113 **Treatment after being lost to follow-up:** A patient after taking treatment for more than one
114 month who returns to treatment following interruption of treatment for two or more consecutive
115 months.

116 **Treatment after failure of New TB regimen:** A patient who has received new regimen for TB
117 and in whom treatment has failed. Failure is defined as sputum smear/culture positive at five
118 months or later during treatment.

119 **Treatment after failure of Retreatment regimen:** A patient who has received retreatment
120 regimen for TB and in whom treatment has failed. Failure is defined as sputum smear/culture
121 positive at five months or later during treatment.

122 **Transfer in:** A patient who has been transferred from another TIC to continue MDR-TB
123 treatment.

124 **Other:** Refers to any DR-TB patient who does not fit into any of the above categories.

125 **Cured:** Treatment completed according to national recommendation without evidence of failure
126 and three or more consecutive cultures taken at least 30 days apart are negative after the
127 intensive phase.

128 **Treatment completed:** Treatment completed according to national recommendation without
129 evidence of failure but no record that three or more consecutive cultures taken at least 30 days
130 apart are negative after the intensive phase.

131 **Treatment failed:** Treatment terminated or need for permanent regimen change of at least two
132 anti-TB drugs because of; lack of conversion by the end of the intensive phase, or bacteriological
133 reversion in the continuation phase after conversion to negative after intensive phase, or evidence
134 of additional acquired resistance to fluoroquinolones or second line injectable drugs, or adverse
135 drug reactions.

136 **Lost To Follow Up (LFTU):** A patient whose treatment was interrupted for two consecutive
137 months or more

138 **Died:** A patient who dies for any reason during the course of treatment

139 **ADR:** A response to a drug which is noxious and unintended, and which occurs at doses
140 normally used in human for the prophylaxis, diagnosis, or therapy of disease, or for the
141 modification of physiological function.

142 **Side Effects:** An expected, well-known reaction resulting in little or no change in patient
143 management.

144 **Data quality control**

145 Four data collectors (Diploma nurse) were trained on the content of the questionnaire and the
146 objective of the study for 03 days. A pre-test was done at 5% of the sample size, at another
147 district before the actual data collection. A structured interviewer administered questionnaire was
148 used for the data collection. The supervisor and the investigator were checked the data for
149 completeness, missing, and unwanted filling daily. Epi data manager version 4.6.0.4 was used
150 for data entry. SPSS version 23 was used for the analysis.

151 **Ethical Consideration**

152 Ethical clearance was obtained from the ethics Institutional Review Board (IRB) of Addis Ababa
153 University. A formal letter from Addis Ababa University was submitted to St. Peter's TB
154 Specialized Hospital and permission was obtained. Written informed consent for participation
155 was not required for this study. To ensure confidentiality, name and other identifiers of the
156 patients were not recorded on the data abstraction formats.

157 **Data processing and Analysis**

158 Data was entered, cleaned and checked for the completeness using Epi data version 4.6 statistical
159 software. Errors related to inconsistency were verified using cross data exploration techniques.
160 Then managed data was exported to Statistical Package for Social Sciences (SPSS) software
161 version 23. Descriptive analysis was done using frequency and percentages for the variables.
162 Logistic regression was used to analyze the associations between different variables. Factors that
163 were associated with ADR at 95% significance level in the bivariate analysis were included in
164 the final multivariate analysis. Statistical significance was declared if the p-value is less than
165 0.05.

166 **Results**

167 **Socio-Demographic Characteristics**

168 The mean age (\pm SD) of the patients who have participated in this survey was 29.58 years (\pm 11.4)
169 and their age ranged from 18 to 75 years. Regarding the sex of the participants 159 (55.6%) were
170 males. More than half, 181 (63.3%) of the patients were from Addis Ababa, followed by the
171 Oromia region 45 (15.7%). Almost equal numbers of the patients are single 136 (47.6%) and
172 married 138 (48.3%). Most of the patients have attended education within the grade levels 1 up
173 to 8, 93 (32.5%) and 9 up to 12, 86 (30.1%) (**Table 1**).

174 **Clinical Characteristics**

175 Most of the patients had pulmonary TB, 270 (94.4%). Additionally, majority of the patients; 244
176 (85.3%) had a prior history of TB treatment (failure, default and relapse cases). The majority of
177 the patients 270 (94.4%) had no co-morbidities while the rest had co-morbidities such as diabetes
178 and cardiomyopathy. The most frequently used 251 (87.8%) treatment regimen was capreomycin
179 (Cm), levofloxacin (Lfx), pyrazinamide (Z), ethionamide (Eto)/Prothionamide (Pto) and
180 cycloserin (Cs). (**Table2**)

181 **Frequency, management and Treatment outcomes of ADR**

182 Out of 286 patients, 169 (59.1%) were found to be experiencing symptoms associated with
183 ADRs. Most of the patients experienced combination of ADRs. The most common ADR was
184 nausea and vomiting (57.4%) followed by dyspepsia and abdominal pain (44%) and arthralgia
185 (43.5%). Other ADRs also included headache (22.5%), insomnia (21.3%), anorexia (18.9%), and
186 others (**Table3**). From 169 patients, proper management of ADR was given for 119(70.4%)

187 patients (**Fig2**). One hundred fifty-three (53.5%) patients completed their treatments. While 78
188 (27.3%) of the patients were cured (**Table 3**).

189 **Treatment regimens used**

190 The highest number 251 (87.8%) of the patients took the standard treatment regimen which is the
191 combination of Cm, Lfx, Pto/ Eto, Cs, Z during the intensive phase and Lfx, Pto/ Eto, Cs, Z
192 during the continuation phase (**Table 4**).

193 **Multivariate analysis of factors and adverse drug reaction**

194 Variables with $P < 0.02$ during the bivariate analysis were included in the multivariate logistic
195 regression analysis to see the effect of confounding variables. The multivariate analysis
196 indicated that comorbidity and treatment outcomes showed statistically significant association
197 with adverse drug reaction. But age and smoking did not show significant association with
198 adverse drug reaction. The odds of adverse drug reaction in patients who had comorbid diseases
199 were about 6 times higher than those who had no the diseases (AOR = 5.809, 95%CI (1.106 -
200 30.504)). Treatment outcome was significantly associated with adverse drug reaction. Patients
201 who had treatment outcome of cure were more likely to develop adverse drug reaction
202 (AOR=10.012, 95% CI, (2.131 - 47.036)) than those who had treatment outcome of failure
203 (**Table 5**)

204 **Discussion**

205 In this study, 59.1 % of the participants developed symptoms associated with ADRs these is
206 higher compared with Previous studies have documented a prevalence rate of 44% in
207 Nigeria(5),50% in India(6),50.5% in Vietnam (7). Another study in India has also found a

208 prevalence of 33.96%(8). This finding is considerably higher than those given in previous reports
209 and the observed variation could be a result of disparity in the definitions of adverse drug
210 reactions used by the researchers, the study design used, the geographic variation, the specific
211 anti-TB drugs used and the time at which the study was conducted.

212 The most common ADR experienced by participants were nausea and vomiting (57.4%)
213 followed by dyspepsia and abdominal pain (44%) and arthralgia (43.5%). Other reported ADRs
214 include headache (22.5%), insomnia (21.3%) and anorexia (18.9%). The result is inconsistent
215 with those reported by (4-8). This difference may be attributed to the difference in the
216 pharmacokinetic parameter of the patients, use of different anti –TB regimens and their doses
217 among countries.

218 The drugs most likely associated with nausea and/or vomiting were capreomycin, levofloxacin,
219 ethionamide/protionamide and pyrazinamide. Most of the aforementioned drugs also cause
220 dyspepsia. This finding is also comparable the other findings reported by Haregewoin and Petros
221 (4, 9, 10).Majority of the patients experienced gastrointestinal symptoms during early weeks of
222 treatment. These symptoms may prevent the delivery of adequate therapy and lead patients for
223 further problem. Gastrointestinal side effects which were commonest can be largely prevented by
224 proper timing and spacing of drugs with food and if necessary, giving antiemetic, antacids and
225 proton pump inhibitors (PPIs) or H2 receptor blockers.

226 Arthralgia was found to be one of the common ADR encountered by patients in this study. It was
227 likely caused by pyrazinamide and levofloxacin(9).The present finding is inconsistent with study
228 findings from India(8).The discrepancy may be due to variation in inclusion of the causative
229 drugs in the national MDR-TB treatment protocol between the countries.

230 This study identified determinants of adverse drug reaction among the patients attending St.
231 Peter hospital in Addis Ababa Ethiopia. Comorbidity and treatment outcome were the
232 independent determinants of adverse drug reaction of the patients. But it found that any of the
233 socio demographic characteristics were not statistically significant with the development of
234 adverse drug reaction.

235 Treatment outcome was significantly associated with adverse drug reaction. The odds of adverse
236 drug reaction in patients whose treatment outcome of cure were about 10 times higher than
237 (AOR=10.012, 95% CI, (2.131 - 47.036)) those whose treatment outcome of failure. The study
238 finding was also in line with studies conducted in India and Russia (6, 10-12). The possible
239 reason could be those patients who were cure might be closely followed by tuberculosis
240 treatment care providers and as a result they got better reporting of ADRs and favorable
241 treatment outcome.

242 The study revealed that MDR-TB patients who had comorbid diseases were about 6 times more
243 likely (AOR = 5.809, 95%CI (1.106 - 30.504)) to develop adverse drug reaction than those who
244 had not the disease. This finding is consistent with previous reports(13-15). In the presence of
245 comorbidities, the patients take several drugs, whether prescription or over the-counter,
246 contributes to the risk of having an ADR. The number and severity of ADRs increases
247 disproportionately as the number of drugs taken increases. It may also be related to medications
248 that are useful in the treatment of one disease may precipitate or worsen another condition.

249 This study showed that history of smoking, alcohol use, drug abuse and socio demographic
250 characteristics such as sex, age, living condition, marital status, educational status and
251 occupation of MDR-TB patients were not significantly associated with the development of

252 adverse drug reactions. However, previous study has reported that age, sex, smoking and alcohol
253 use had significant association with adverse drug reactions (4, 16-20). The possible explanation
254 for this disparity might be the existence of variation with regard to genetic factors, culture, belief
255 and living conditions. It might also be related to difference in the number of study participants
256 used among the studies.

257 **Strengths and Limitations of the study**

258 Clinical record reviewed using pre-tested structured data collection format which minimize
259 information bias. Data quality was assured by trained nurse data collectors and close supervision.

260 The use of complete data from registers and patient cards, and for the reporting of adverse drug
261 reactions and associated factors is also one the strength of this study. Whereas the Reporting bias
262 might exist, as data were obtained retrospectively through medical card review, especially for
263 adverse events not defined by laboratory tests, such as gastrointestinal disorders, which might
264 overestimate or underestimate the magnitude of adverse events. Some important confounding
265 factors might not have been collected in this study. Electronic medical records are designed for
266 daily use in hospital clinical diagnosis and treatment, not for analysis of adverse reactions/events
267 of drugs used, so the records might lack some information needed to detect adverse events, and
268 these were likely to result in bias of the study.

269 **Conclusion and recommendation**

270 During the study period, the prevalence of adverse drug reaction among MDR-TB patients was
271 found to be higher. Majority of the study participants experienced more than one adverse drug

272 reactions. Nausea, vomiting followed by dyspepsia and abdominal pain and arthralgia were the
273 commonly reported ADRs.

274 The study showed that comorbidity and treatment outcomes were the independent determinants
275 adverse drug reaction among MDR-TB patients in the hospital. However, socio-demographic
276 variables and behavioral factors were not significantly associated with the development of ADRs

277 Based on the finding of this study, the following important recommendations are forwarded
278 management strategies should be strengthened to minimize ADR occurrence and for better
279 treatment outcome. MDR-TB Patients having comorbid diseases should be closely monitored
280 and gave special counseling to minimize the development of ADRs. Patients should be educated
281 on the possible ADRs of MDR-TB drugs. Further investigation should be performed
282 emphasizing the occurrence of adverse events in different phases of MDR-TB treatment, and
283 corresponding relationships with comorbidities, sociodemographic and behavioral variables.

284 **Disclosure**

285 The authors reports no both financial and non -financial competing interest in these works

286 **Reference**

- 287 1.Federal minstry of Health(FMOH) Tuberculosis, Leprosy, and TB/HIV Prevention and Control
288 Programme Manual, 4th ed., Addis Ababa, Ethiopia. 2008.
- 289 2.FMHACA. Guideline for Adverse Drug Events Monitoring (Pharmacovigilance), 3rd ed., Addis Ababa,
290 Ethiopia. 2014.
- 291 3.World Health Organization(WHO). Global Tuberculosis Report, 20th ed., Geneva. 2015.

- 292 4.Haregewoin B. DS, Getnet Y, Tesfamariam, M. Prevalence and Risk Factors of Adverse Drug Reactions
293 Associated Multidrug Resistant Tuberculosis Treatments in Selected Treatment Centers in Addis Ababa
294 Ethiopia. *Journal of Tuberculosis Research*, 2, 144-154. 2014;2:144-54.
- 295 5.Yohanna KA. PI, Sven GH. Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with
296 Multidrug-Resistant Tuberculosis in Nigeria. *Journalpone* 2015;10(3).
- 297 6.S. S. Shin ADP, I. Y. Gelmanova Adverse reactions among patients being treated for MDR-TB in
298 Tomsk, Russia. . *The International Journal of Tuberculosis and Lung Disease* 2007;11(12):1314–20.
- 299 7.Nguyen BH. NV, Pham HK., Nguyen VH, Bui TTQ. Adverse events in the treatment of MDR-TB
300 patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam. . *BMC*
301 *Research Notes* 2015;8:809.
- 302 8.Kishor BR. MS, Avinash RL., Sanjay LS., Gajanan AS., Vimlesh RP. . Adverse events among patients
303 of multi drug resistant tuberculosis receiving second line anti TB treatment. *International Journal of*
304 *Scientific Reports*. 2015;1(6):253-7
- 305 9.Petros I, Bhanumati, V., Homa, M., Helen, S.C., Joanna, L., Peter, S., Esdras, S., Samsuddin, K., Roma,
306 P., Zarir, U., Giovanni, B.M., Giovanni, S, Tony, R. Adverse Events among HIV/MDR-TB Co-Infected
307 Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. . *PLoS ONE*
308 2012;7: e40781.
- 309 10.Dela AI TN, Singh AP, Piparva KG. Adverse drug reactions and treatment outcome analysis of
310 DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
311 *Lung India: official organ of Indian Chest Society*. 2017;34(6):522–6.
- 312 11.Dominica C, Cristian, D., Niculae, G., Radu, P. and Constantin, M. . Individualized Treatment
313 Regimens with Second Line Anti-TB Drugs (SLD) Compared to First Line Anti-TB Drug (FLD) Only in
314 New Pulmonary TB Patients, Culture Confirmed with Full Sensibility at Drug Sensibility Test (DST). .
315 *Thematic Poster Session*, 4406. 2011.
- 316 12.Mahajan S, Tandon, V.R, Kuma, S. Women and Risk for Developing ADR's. *JK Science* 2012;14(1).

- 317 13.JA M. Factors affecting the development of adverse drug reactions (Review article).Saudi
318 Pharmaceutical Journal 2012;22:83-94.
- 319 14.WHO. A practical handbook on the pharmacovigilance of drugs used in the treatment of tuberculosis:
320 Enhancing the safety of the TB patient. WHO document WHO/CDS/TB. 2012.
- 321 15.Sangita VP. NK, Alpesh B., Kalpita SS., Kedar GM, Lipy KS. Adverse Drug Reactions in Patients put
322 on Multi Drug Resistant Tuberculosis (MDR-TB) Treatment in Seven Districts of Central Gujarat. .
323 Journal of Young Pharmacists 2015;7(4).
- 324 16.Rohan H. ASK, G. N. Dakhale , Nilesh G. A Prospective, Observational Study of Adverse Reactions
325 to Drug Regimen for Multi-Drug Resistant Pulmonary Tuberculosis in Central India. Mediterranean
326 Journal of Hematology and Infectious Diseases 2014;6(1).
- 327 17.A. S. Assessment of Knowledge Attitude and Practices of Tuberculosis Patients Towards Tuberculosis
328 and its Treatment in Addis Ababa City Government, Ethiopia, MPH thesis, Addis Ababa University,
329 Addis Ababa. 2011.
- 330 18.J. J.Furin CDM, S. S. Shin.The International Journal of Tuberculosis and Lung Disease.
331 2001;5(7):648–55.
- 332 19.M. G. Prevalence of MDR-TB and Treatment Outcome Among Tuberculosis Patients Attending at St.
333 Peter TB Specialized Hospital Addis Ababa, Ethiopia, MSc thesis, Addis Ababa University, Addis
334 Ababa. 2014.
- 335 20.J. S. Akshata AC, R. Swapn, Shashidhar B., M. Somashekar. Adverse Drug Reactions in Management
336 of Multi Drug Resistant Tuberculosis, in Tertiary Chest Institute. Journal of Tuberculosis Research
337 2015;3:27-33.

338

339 List of tables

340 **Table 1: Socio-demographic characteristics of MDR-TB patients attending St. Peter**
341 **hospital, Addis Ababa, 2020.**

Variable	Frequency	Percent
Sex		
Female	127	44.4
Male	159	55.6
Age group (years)		
18-27	166	58.3
28-37	68	23.9
38-47	26	8.8
48-57	11	3.9
>58	15	5.3
Marital status		
Single	136	47.6
Married	138	48.3
Separated	4	1.4
Divorced	8	2.8
Region		

Addis Ababa	181	63.3
Oromia	45	15.7
SNNPR	24	8.4
Others**	36	12.4
Educational status		
Unable to read and write	27	9.4
Read and write	30	10.5
Grade 1-8	99	34.6
Grade 9-12	86	30.1
Certificate/ Diploma	18	6.3
Degree and above	26	9.1
Occupational status		
Governmental employee	30	10.5
Non-governmental employee	19	6.6
Daily laborer	17	5.9
Self-employed	75	26.2
Unemployed	18	6.3

Student	75	26.2
Others***	52	18.2

342

343 Table 2: Clinical characteristics of MDR-TB patients attending St. Peter hospital, Addis Ababa,

344 2020.

Characteristics	Frequency	Percent
Site TB		
PTB	270	94.4
EPTB	16	5.6
Registration group		
New	42	14.7
Relapse	43	15.0
After lost to follow up	6	2.1
After failure of first treatment	121	42.3
After failure of re-treatment	74	25.9
Previous second line drug use		
Yes	11	3.85
No	275	96.15
Co-morbidities		
Yes	17	5.90
No	269	94.10

Base-line BMI category		
<18.5Kg/m2	186	65.03
18.5-24.9Kg/m2	97	33.92
>=24.9 Kg/m2	3	1.05

345 Table 3: Adverse drug reactions which occurred among the patients attending St. Peter hospital,
 346 Addis Ababa, 2020.

ADR	Frequency	Percent
Rash	12	7.1
Nausea and vomiting	97	57.4
Dyspepsia and abdominal pain	74	44
Diarrhea	8	4.7
Hepatitis	3	1.8
Arthralgia	73	43.5
Electrolyte abnormalities	5	3
Nephrotoxicity	9	5.4
Ototoxicity	8	4.8
Peripheral neuropathy	13	7.7
Depression	12	7.1
Headache	38	22.5
Psychosis	12	7.1
Seizures	2	1.2

Hypothyroidism	2	1.2
Anxiety	11	6.5
Insomnia	36	21.3
Visual disturbances	14	8.3
Musculoskeletal pain	10	6
Vestibular toxicity	10	6
Anorexia	32	18.9
Pain at the injection site	5	3
Others***	27	16

347 ***Fever, sweating, body weakness, anemia, weight loss, palpitation, fungal infection, vaginal
 348 discharge.

349 **Table 4:** Treatment outcomes and the most common anti-TB regimens used among patients in
 350 St. Peter hospital, Addis Ababa, 2020.

Treatment outcomes	Frequency	Percent
Cured	78	27.3
Completed	153	53.5
Lost to follow up	23	8.0
Died	23	8.0
Failure	9	2.1
Regimen		
Cm, Lfx, Pto/ Eto, Cs, Z	251	87.8
Cm, Lfx, Pto/ Eto, Cs, PAS, Z	12	4.2

Cm, Lfx, E, Pto/ Eto, Cs, Z	6	2.1
-----------------------------	---	-----

351


352 Table 5: Multivariate analysis of factors for Adverse Drug Reaction among the patients attending

353 St. Peter hospital, Addis Ababa, 2020.

Variables	COR (95%CI)	P value	AOR (95%CI)	P value
Age group (years)				
18-27	0.486(0.165 - 1.429)	0.190	1.098(0.306 - 3.938)	0.886
28-37	0.496(0.159 - 1.549)	0.227	0.960(0.251 - 3.671)	0.952
38-47	0.200(0.050 - 0.794)	0.022	3.632(0.778 - 16.949)	0.101
48-57	0.250(0.047 - 1.344)	0.106	3.311(0.480 - 22.849)	0.224
>58	1		1	
History of Cigarette Smoking				
Yes	4.792(1.061 - 21.649)	0.042	2.889(0.510 - 16.367)	.231
No	1		1	
Co-morbidities				
Yes	5.601(1.256 - 24.976)	0.024	5.809(1.106 - 30.504)	0.038
No	1		1	
Treatment outcomes				

Cured	0.104(0.024 - 0.462)	0.003	10.012(2.131 - 47.036)	0.004
Complete	0.730(0.189 - 2.823)	0.648	1.367(0.334 - 5.601)	0.664
LTFU	1.829(0.374 - 8.937)	0.783	0.657(0.126 - 3.426)	0.618
Died	1.829(0.374 - 8.937)	0.456	0.366(0.064 - 2.083)	0.257
Failure	1		1	


354 List of figures



355

356 Figure 1: Schematic representation of selection of patient profile cards among the patients

357 attending St. Peter hospital, Addis Ababa, 2009 – 2016.



358
359 Fig 2: Management of ADR among the patients attending St. Peter hospital, Addis Ababa, 2009
360 – 2016.